middle.news
Argent BioPharma narrows loss, secures $11M funding and global CannEpil license
5:23pm on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Argent BioPharma narrows loss, secures $11M funding and global CannEpil license
5:23pm on Monday 31st of August, 2026 AEST
Key Points
Net loss reduced to $7.7 million from $17.8 million
Global CannEpil® licensing deal with Splash Beverage Group extinguishes $7.4M secured debt
Acquisition of full interest in CannPal Animal Therapeutics expands veterinary portfolio
Administrative expenses halved following prior year one-off costs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE